乳腺癌新辅助化疗后乳腺X线摄影微钙化的术前评估
单中心回顾性研究纳入2015年6月至2018年8月96例新辅助化疗后乳腺X线摄影显示瘤床内或附近可疑微钙化的乳腺癌患者,评估残留微钙化对残留肿瘤的预测价值。10例(10.4%)达到病理完全缓解且原可疑微钙化对应良性病理;未达pCR的86例中,61.5%(59/96)残留微钙化对应浸润性或原位癌,28.1%(27/96)对应良性病理。激素受体阳性患者残留恶性微钙化比例高于激素受体阴性患者(48.9% vs 13.5%,p=0.019);MRI预测残留肿瘤范围的ICC为0.709,优于乳腺X线摄影残留微钙化的0.365。
要点
- 新辅助化疗后乳腺X线摄影残留微钙化范围与残留癌范围在38.5%的女性中不相关。
- 激素受体阳性患者残留恶性微钙化比例高于激素受体阴性患者(48.9% vs 13.5%,p=0.019)。
- MRI预测残留肿瘤范围的ICC为0.709,优于乳腺X线摄影残留微钙化的0.365。
关键影像表现/征象
- 10例(10.4%)达到病理完全缓解,原可疑微钙化对应良性病理。
- 未达pCR的86例中,61.5%(59/96)残留微钙化对应浸润性或原位癌,28.1%(27/96)对应良性病理。
诊断标准与关键数值
- 激素受体阳性患者残留恶性微钙化比例为48.9%,激素受体阴性患者为13.5%(p=0.019)。
- MRI预测残留肿瘤范围的ICC为0.709,乳腺X线摄影残留微钙化的ICC为0.365。
- 激素受体阴性/HER2阳性亚型MRI与残留肿瘤大小的ICC为0.925,激素受体阴性/HER2阴性亚型为0.876。
临床应用与阅片要点
- 新辅助化疗后乳腺X线摄影残留微钙化范围与残留癌范围在38.5%的女性中不相关,阅片报告时需结合MRI评估残留肿瘤范围。
- MRI预测残留肿瘤范围优于乳腺X线摄影残留微钙化(ICC 0.709 vs 0.365),激素受体阴性/HER2阳性及激素受体阴性/HER2阴性亚型中MRI与残留肿瘤大小相关性更高(ICC分别为0.925和0.876)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
AIM: To assess the predictive value of preoperative residual mammographic microcalcifications for residual tumours after neoadjuvant chemotherapy (NAC) for breast cancer.
MATERIALS AND METHODS: This single-centre retrospective study included breast cancer patients who underwent NAC and demonstrated suspicious microcalcifications within or near the tumour bed on mammography from June 2015 to August 2018. The residual microcalcifications and remnant lesion on magnetic resonance imaging (MRI) were correlated with histopathological findings of residual tumours and immunohistochemical markers.
RESULTS: A total of 96 patients were included. Ten patients achieved pathological complete response (pCR) and previous suspicious microcalcifications were associated with benign pathology in 10.4% (10/96) of the patients. In the remaining 86 patients who did not achieve pCR, 61.5% (59/96) of the residual microcalcifications were associated with invasive or in situ carcinoma and 28.1% (27/96) with benign pathology. Hormone receptor-positive (HR+) patients had the highest proportion of residual malignant microcalcifications compared to HR- patients (48.9% versus 13.5%, respectively; p=0.019). MRI correlated better than residual microcalcifications on mammography in predicting residual tumour extent in all subtypes (ICC=0.709 versus 0.365). MRI also showed higher correlation with residual tumour size for the HR-/HER2+ and HR-/HER2- subtype (ICC=0.925 and 0.876, respectively).
CONCLUSION: The extent of microcalcifications on mammography after NAC did not correlate with the extent of residual cancer in 38.5% of women. Regardless of the extent of microcalcifications, residual tumour extent on MRI after NAC and molecular subtype could be an accurate tool in evaluating residual cancer after NAC.
引用
- Kim EY, Do SI, Yun JS, et al. Preoperative evaluation of mammographic microcalcifications after neoadjuvant chemotherapy for breast cancer. Clin Radiol. 2020. PMID: 32291081. doi:10.1016/j.crad.2020.03.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。